Back to results
US 2024/0002812 A1Published application
Methods of preparing gene therapies
AssigneeBridgeBio Services Inc.
InventorsAshton LAVOIE, Jeffrey Zugates
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods for purifying gene therapy compositions using anion exchange chromatography.
Claims34
A method, comprising:
- a) providing a mixture comprising a plurality of recombinant adeno-associated (rAAV) vector particles and one or more impurities, wherein rAAV vector particles of said plurality of rAAV vector particles each include a therapeutic nucleic acid molecule, and wherein said one or more impurities comprise rAAV vector particle aggregates, rAAV vector particles that do not include said therapeutic nucleic acid molecule, and aggregates of rAAV vector particles and rAAV vector particles that do not include said therapeutic nucleic acid molecule;
- b) contacting an anion exchange column with said mixture;
- and
- c) contacting said anion exchange column with a first elution buffer and a second elution buffer to provide an eluate, wherein said eluate comprises rAAV vector particles of said plurality of rAAV vector particles,
- wherein said first elution buffer comprises magnesium sulfate;
- and
- wherein said second elution buffer comprises magnesium sulfate and magnesium chloride.
4 more elements
(canceled)
(canceled)
(canceled)
A method, comprising:
- a) providing a mixture comprising a plurality of recombinant adeno-associated (rAAV) vector particles and one or more impurities, wherein rAAV vector particles of said plurality of rAAV vector particles each include a therapeutic nucleic acid molecule, and wherein said one or more impurities comprise rAAV vector particle aggregates, rAAV vector particles that do not include said therapeutic nucleic acid molecule, and aggregates of rAAV vector particles and rAAV vector particles that do not include said therapeutic nucleic acid molecule;
- b) contacting an anion exchange column with said mixture;
- and
- c) contacting said anion exchange column with a first elution buffer and a second elution buffer to provide an eluate, wherein said eluate comprises rAAV vector particles of said plurality of rAAV vector particles,
- wherein said first elution buffer comprises a sulfate salt;
- and
- wherein said second elution buffer comprises a sulfate salt and a chloride salt.
4 more elements
A method, comprising:
- a) providing a mixture comprising a plurality of recombinant adeno-associated (rAAV) vector particles and one or more impurities, wherein rAAV vector particles of said plurality of rAAV vector particles each include a therapeutic nucleic acid molecule, and wherein said one or more impurities comprise rAAV vector particle aggregates, rAAV vector particles that do not include said therapeutic nucleic acid molecule, and aggregates of rAAV vector particles and rAAV vector particles that do not include said therapeutic nucleic acid molecule;
- b) contacting an anion exchange column with said mixture;
- and
- c) contacting said anion exchange column with a first elution buffer and a second elution buffer to provide an eluate, wherein said eluate comprises rAAV vector particles of said plurality of rAAV vector particles,
- wherein said first elution buffer comprises a first salt;
- and
- wherein said second elution buffer comprises a second salt and a third salt, wherein the total salt concentration of said second elution buffer is between about 40-250 millimolar (mM).
4 more elements
(canceled)
-13. (canceled)
-16. (canceled)
(canceled)
(canceled)
-23. (canceled)
(canceled)
-33. (canceled)
-36. (canceled)
(canceled)
-47. (canceled)
-62. (canceled)
Dependencies are inferred from the claim text.